IgA EGFR antibodies mediate tumour killing in vivo
Article first published online: 5 AUG 2013
Copyright © 2013 EMBO Molecular Medicine
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 5, Issue 8, pages 1213–1226, August 2013
How to Cite
Boross, P., Lohse, S., Nederend, M., Jansen, J. H. M., van Tetering, G., Dechant, M., Peipp, M., Royle, L., Liew, L. P., Boon, L., van Rooijen, N., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T. and Leusen, J. H. W. (2013), IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med, 5: 1213–1226. doi: 10.1002/emmm.201201929
- Issue published online: 5 AUG 2013
- Article first published online: 5 AUG 2013
- Manuscript Accepted: 8 JUN 2013
- Manuscript Revised: 6 JUN 2013
- Manuscript Received: 23 AUG 2012
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Figure S1. ADCC assay with human PBMC. (A) Specific killing of A1207 cells by human PBMC in a 4 h 51 Cr-release assay. (B) Specific killing of A1207 cells with 1 μg/mL EGFR antibodies by monocytes isolated from PBMC fractions and tested in a 4 h 51 Cr-release assay. Source data is available for this figure in the Supporting Information.
Figure S2. Cytofluorimetric analysis of G-CSF-primed mouse whole blood. (A) Mice were injected subcutaneously with 20 μg of G-CSF and bled via the retro-orbital plexus four days later. Blood was analysed by cytofluorimetry and the number of effector cells was analysed relative to known amount of beads. (B) Expression of mouse FcγR and human FcαRI on different populations in the blood was analysed by staining with specific antibodies. Unstimulated and PEG-G-CSF-stimulated wild-type and FcαRI transgenic mice are compared. Source data is available for this figure in the Supporting Information.
Figure S3. N-glycan sequencing profiles of antibodies N-glycoprofiling of IgA1 EGFR (A) and IgA2 EGFR (B) antibodies: the reduced and alkylated antibodies were immobilized in a polyacrylamide gel block before releasing the N-glycans by PNGaseF. The glycans were fluorescently labelled with 2-AB and analysed on an ACQUITYUPLC-BEH-Glycan column. A combination of the retention times standardized to glucose units (GU) and exoglycosidase digestions were used to determine the sequence of the glycans. Source data is available for this figure in the Supporting Information.
Figure S4. Efficacy of depletion of specific cell types (A) PMN depletion efficacy. WT Balb/c mice were injected with tumor cells and two times with 200 μg isotype control or with Gr-1 depleting antibody (Ly6G/C-specific). The effector cells from the peritoneal lavage were identified by FACS staining. (B) Macrophage depletion efficacy. WT Balb/c mice were injected with 200 μL chlodronate liposomes or PBS before the experiment to deplete macrophages. Mice received 50 μg IgA2 EGFR and the effector cells from the peritoneal lavage were identified by FACS staining. Source data is available for this figure in the Supporting Information.
Table S1. Half-life of IgG1 and IgA1 EGFR. Source data is available for this figure in the Supporting Information.
Table S2. A summary of the types of N-glycans on IgA1 EGFR and IgA2 EGFR. Source data is available for this figure in the Supporting Information.
|emmm201201929.reviewer_comments.pdf||PDF document||479K||Review Process File|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.